Xiaoling Cai

Fujian Medical University — China

Medicine · Health Sciences

34h-index4.0kcitations304works2.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Diabetes Treatment and Management(106), Diabetes Management and Research(54), Metabolism, Diabetes, and Cancer(49), Pancreatic function and diabetes(45), Diabetes, Cardiovascular Risks, and Lipoproteins(25)

Publications304 total

Intensive blood pressure reduction but an increased risk of peripheral arterial disease: a systematic review and meta-analysis of randomized controlled trials
Annals of Medicine·2025Open Access
Morning spot urinary cortisol-to-creatinine ratio: a novel screening tool for assessing excess cortisol secretion
Frontiers in Endocrinology·2025Open Access
Weight Loss, Obesity Medication, and Risk of Obesity‐Associated Cancer: A Meta‐Analysis of Randomized Controlled Trials
Obesity·2025
Control of the cardiovascular risk factors in patients with type 2 diabetes mellitus in China in 2023–2024
Diabetes Obesity and Metabolism·2025
Anti-diabetic medications and cancer: links beyond glycemic and body weight control
Precision Clinical Medicine·2025· 1 citedOpen Access
Rare case of longevity in Hutchinson-Gilford progeria syndrome and literature review
Orphanet Journal of Rare Diseases·2025Open Access
Characterizing echocardiographic abnormalities and their associated factors in patients with type 1 diabetes: a cross-sectional study
Cardiovascular Diabetology·2025Open Access
Regional, age-specific and sex-specific trends in the prevalence of overweight or obesity in type 1 diabetes from 1980 to 2020: a meta-analysis of 78 observational studies with 650,265 participants
Diabetes Research and Clinical Practice·2025· 2 cited
Risk factors for progression to albuminuria in individuals with newly diagnosed type 2 diabetes: a 5-year cohort study
BMC Endocrine Disorders·2025Open Access
Review for "Effectiveness and predictors of weight reduction with low-dose tirzepatide in Japanese patients with type 2 diabetes: A pilot retrospective cohort study"
2025
Review for "Evolving trends of antidiabetic agents stratified by age, kidney function and body mass index: Insights from a nationwide claims database"
2025
PCSK9 Inhibitor and Potential Decreased Risk of Neoplasms, Especially in Females: A Meta-Analysis
Pharmaceuticals·2025Open Access
Trajectory of the body weight after drug discontinuation in the treatment of anti-obesity medications
BMC Medicine·2025· 10 citedOpen Access
Cardiovascular and brain effects of liraglutide in transthyretin amyloidosis (ATTR) mice models
International Journal of Medical Sciences·2025Open Access
Glucagon‐like peptide‐1 receptor agonist treatment associated weight fluctuation and influencing factors in patients with overweight or obesity
Diabetes Obesity and Metabolism·2025· 1 citedOpen Access
848-P: The Antidiabetic Medication Treatment Patterns in Chinese Patients with Type 2 Diabetes—Real-World Evidence from ICaReMe China Registry Study
Diabetes·2025· 1 cited
1730-P: The Antiobesity Medications and Renal Outcomes, One Answer But with Multiple Implications—A Meta-analysis of Randomized Controlled Trials
Diabetes·2025
1723-P: Weight Reduction Mediated by Antiobesity Medications and the Risk of Obesity-Associated Cancer—A Meta-analysis of Randomized Controlled Trials
Diabetes·2025
789-P: The Use of Antiobesity Medications and the Increased Risk of Alopecia—A Meta-analysis of Randomized Controlled Trials
Diabetes·2025
440-P: Associated Factors with Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in iCaReMe China Registry
Diabetes·2025
page 1 of 16Next →

Frequent Co-authors

Linong Ji(25), Xueyao Han(20), Wenjia Yang(19), Xueying Gao(10), Linong Ji(9), Simin Zhang(7), Fang Lv(7), Yingying Luo(7), Zhigang She(6), Yongcheng Lin(6), Yifei Chen(6), Xianghai Zhou(6), Chu Lin(6), Siqian Gong(5), Xingyun Zhu(4), Lin Nie(4), Lingli Zhou(4), Chang‐Lun Shao(3), Xuekui Xia(3), Lingli Zhou(3)